Real-World Use and Impact of VMAT2 Inhibitors in Patients with Tardive Dyskinesia

被引：0
|
作者：
Lundt, L. [1 ]
Franey, E. [1 ]
Yonan, C. [1 ]
机构：
[1] Neurocrine Biosci Inc, San Diego, CA USA
来源：
MOVEMENT DISORDERS | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
102
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [21] The Clinical and Economic Burden of Tardive Dyskinesia in Israel Real-World Data Analysis
    Barer, Yael
    Ribalov, Rinat
    Yaari, Ayelet
    Maor, Ron
    Arow, Qais
    Logan, John
    Chodick, Gabriel
    Arkadir, David
    Eitan, Renana
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2022, 42 (05) : 454 - 460
  • [22] Dissemination of VMAT-2 Inhibitors: A New Class Drug for Tardive Dyskinesia and Huntington Disease
    Ma, Erica
    Krening, Emma
    Bruno, Michiko K.
    NEUROLOGY-CLINICAL PRACTICE, 2025, 15 (01)
  • [23] Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors
    McCary, Isabella
    Guelcher, Christine
    Kuhn, Jan
    Butler, Regina
    Massey, Gita
    Guerrera, Michael F.
    Ballester, Lance
    Raffini, Leslie J.
    BLOOD, 2019, 134
  • [24] Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl, Stephen M.
    CNS SPECTRUMS, 2018, 23 (04) : 239 - 247
  • [25] Utility of VMAT2 inhibitors in management of stereotypy in children: a series of six patients
    Hull, M.
    Parnes, M.
    MOVEMENT DISORDERS, 2020, 35 : S523 - S523
  • [26] New generation VMAT2 inhibitors induced parkinsonism
    Vasireddy, Rani Priyanka
    Sokola, Brent
    Guduru, Zain
    CLINICAL PARKINSONISM & RELATED DISORDERS, 2020, 3
  • [27] RE-KINECT, A REAL-WORLD, PROSPECTIVE TARDIVE DYSKINESIA SCREENING STUDY: AN EVALUATION OF BASELINE CHARACTERISTICS IN OLDER PATIENTS
    Caroff, Stanley
    Cutler, Andrew
    Tanner, Caroline
    Yeomans, Karen
    Lenderking, William
    Shalhoub, Huda
    Chen, Jun
    Anthony, Ericha
    Yonan, Chuck
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2019, 27 (03): : S176 - S179
  • [28] VMAT2 inhibitors for the treatment of hyperkinetic movement disorders
    Koch, Jessa
    Shi, Wei-Xing
    Dashtipour, Khashayar
    PHARMACOLOGY & THERAPEUTICS, 2020, 212
  • [29] Development of fluorescent substrates for vesicular monoamine transporter 2 (VMAT2) and their application in high throughput screening of VMAT2 inhibitors
    Hu, Gang
    Sames, Dalibor
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [30] Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study
    Tanner, Caroline M.
    Caroff, Stanley N.
    Cutler, Andrew J.
    Lenderking, William R.
    Shalhoub, Huda
    Page, Veronique
    Franey, Ericha G.
    Serbin, Michael
    Yonan, Chuck
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2023, 7 (01)
12345